Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice

Aim/hypothesis Combination therapy targeting the major actors involved in the immune-mediated destruction of pancreatic beta cells appears to be an indispensable approach to treat type 1 diabetes effectively. We hypothesised that the combination of an orally active pan-histone deacetylase inhibitor...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetologia 2018-02, Vol.61 (2), p.389-398
Hauptverfasser:	Besançon, Alix, Goncalves, Tania, Valette, Fabrice, Dahllöf, Mattias S., Mandrup-Poulsen, Thomas, Chatenoud, Lucienne, You, Sylvaine
Format:	Artikel
Sprache:	eng
Schlagworte:	Autoimmunity Beta cells Diabetes Human Physiology IL-1β Immunotherapy Insulin Internal Medicine Lymphocytes T Medicine Medicine & Public Health Metabolic Diseases Remission (Medicine)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!